Precision Medicine and PET-Computed Tomography in Pediatric Malignancies

Yasemin Sanli; Ebru Yilmaz; Rathan M Subramaniam

doi:10.1016/j.cpet.2017.05.009

Precision Medicine and PET-Computed Tomography in Pediatric Malignancies

PET Clin. 2017 Oct;12(4):423-435. doi: 10.1016/j.cpet.2017.05.009. Epub 2017 Jul 28.

Authors

Yasemin Sanli¹, Ebru Yilmaz², Rathan M Subramaniam³

Affiliations

¹ Department of Nuclear Medicine, Medical Faculty of Istanbul, Istanbul University, Sehremini, Istanbul 34370, Turkey; Department of Radiology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA. Electronic address: yasemin.sanli@UTsouthwestern.edu.
² Department of Nuclear Medicine, Medical Faculty of Istanbul, Istanbul University, Sehremini, Istanbul 34370, Turkey.
³ Department of Radiology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Department of Clinical Sciences, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Department of Biomedical Engineering, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA.

PMID: 28867113
DOI: 10.1016/j.cpet.2017.05.009

Abstract

Fluorine-18 fluorodeoxyglucose (¹⁸F-FDG) PET-computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose ¹⁸F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT-based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine (¹³¹I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients. It may predict histologic differentiation and neoadjuvant therapy assessment in Wilms tumor.

Keywords: PET; PET/CT; Pediatric malignancies.

Publication types

Review

MeSH terms

Child
Fluorodeoxyglucose F18
Humans
Neoplasms / diagnostic imaging*
Neoplasms / therapy
Positron Emission Tomography Computed Tomography*
Precision Medicine*
Radiopharmaceuticals

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18